Response: The coagulation laboratory monitoring of AFSTYLA single-chain FVIII concentrate

Haemophilia

Volumn 24, Issue 3, 2018, Pages e129-e131

  Friedman, K D ^a   Powell, J S ^b   Bensen Kennedy, D ^b  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b CSL BEHRING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGENIC SUBSTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8;

BIOASSAY; CHROMOGENIC SUBSTRATE ASSAY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL PROTOCOL; COAGULATION LABORATORY MONITORING; FIELD STUDY; HEALTH CARE PLANNING; HEALTH LITERACY; HEMOPHILIA A; LETTER; MONITORING; ONE STAGE ASSAY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RISK REDUCTION; TOTAL QUALITY MANAGEMENT; BLOOD CLOTTING; LABORATORY;

BLOOD COAGULATION; FACTOR VIII; LABORATORIES;

EID: 85044618885     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13450     Document Type: Letter

References (10)

1. Bowyer A, Key N, Dalton D, Kitchen S, Makris M. The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate. Haemophilia. 2017;23:e469-e470.
2. Mikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin Thromb Hemost. 2002;28:257-264.
3. Sommer JM, Moore N, McGuffie-Valentine B, Bardan S, Buyue Y, Kamphaus GD, et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia. 2014;20:294-300.
4. Turecek PL, Romeder-Finger S, Apostol C, Bauer A, Crocker-Buque A, Burger DA, et al. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia. 2016;22:957-965.
5. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia. 2011;17:695-702.
6. Ingerslev J, Jankowski MA, Weston SB, Charles LA, ReFacto Field Study P. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004;2:623-628.
7. CSL Behring. AFSTYLA Prescribing Information. 2017.
8. St Ledger K, Feussner A, Kalina U, Metzner H, Horn C, Stowers A, et al. Characteristics of rVIII-SingleChain in the one-stage and the chromogenic substrate assay: results of an international field study. Haemophilia. 2016;22(Suppl. 4):59.
9. St Ledger K, Feussner A, Kalina U, Horn C, Metzner HJ, Bensen-Kennedy D, et al. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories. J Thromb Haemost. 2018;16:555-564.
10. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14:248-261.